News

Boston Scientific announced its support of the HORIZONS II AMI clinical trial, which is designed to evaluate the safety and efficacy of the Promus Element Plus everolimus-eluting platinum chromium...

Two-year follow-up data from the pivotal PLATINUM Workhorse trial comparing the safety and effectiveness of the Promus Element and Xience V everolimus-eluting coronary stents demonstrated superior...

March 29, 2012 — In the second year of an ongoing trial, the Resolute zotarolimus-eluting stent (Medtronic) achieved a low rate of stent thrombosis, cardiac death, target vessel heart attack and...

Biodegradable polymer drug-eluting stents (DES) provide better long-term safety and efficacy than durable polymer DES, according to findings from an analysis of three major clinical trials — ISAR-...

March 20, 2012 - MarBlue Medical announced the global product launch of its CE-marked drug-eluting balloon (DEB) Protege as well as its CoCr stent on DEB Pioneer. The full market launch of the new...

March 16, 2012 — The U.S. Food and Drug Administration (FDA) approved the premarket approval (PMA) application for the Covidien EverFlex self-expanding peripheral stent system.

March 16, 2012 - Depression increases the risk of death in patients who have a coronary stent implanted. After seven years of follow up, depressed patients were 1.5 times more likely to have died...

March 9, 2012 — Boston Scientific Corp. announced the launch of the Promus Element everolimus-eluting coronary stent system in Japan. The product was recently approved by the Ministry of Health,...

March 6, 2012 — In a development that brings advanced combination therapy treatment of peripheral artery disease (PAD) to Japanese patients for the first time, Cook Medical has received PMDA...

The U.S. Food and Drug Administration (FDA) granted the first coronary stent indication for use in patients experiencing an acute myocardial infarction (AMI), or heart attack. The Boston...

February 20, 2012 —Medtronic announced U.S. Food and Drug Administration (FDA) approval of the Resolute Integrity drug-eluting stent (DES)...

February 6, 2012 — InspireMD Inc. announced positive clinical results for its MGuard stent from a controlled randomized trial conducted in Chile.

February 6, 2012 — A medical technology company commercializing the world's first and only self-apposing stent to treat acute myocardial infarction (AMI), announced today that the APPOSITION III...

February 1, 2012 — Boston Scientific announced the first patient use and European market launch of the Promus Element Plus everolimus-eluting coronary stent system. The first patient implant in...

January 23, 2012 – Boston Scientific Corp. said the U.S. District Court for the District of New Jersey has found all the asserted patents for a coronary stent in a lawsuit brought by Johnson...

January 18, 2012 — Boston Scientific reported nine-month clinical endpoint data from its ORION trial, demonstrating positive outcomes for the Epic self-expanding nitinol stent in patients with...

January 9, 2012 – A registry that includes every patient in Sweden having percutaneous coronary intervention (PCI) found use of newer generation drug-eluting stents (DES) is associated with lower...

January 4, 2012 – ECRI, an independent nonprofit that researches the best approaches to improving patient care, listed 10 health technology issues that hospital leaders should have on their watch...

Abbott announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit drug-eluting bioresorbable vascular scaffold (...

December 20, 2011 – Boston Scientific reported positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the Ion (Taxus...